Sorry, you need to enable JavaScript to visit this website.

Frequently Asked Questions (FAQs) | DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)

FAQs About Darzalex FASPRO®

Here are some of the more frequently asked questions about DARZALEX FASPRO®. Click on the question to reveal the answer.

DARZALEX FASPRO® is a prescription medicine that is used to treat adults with multiple myeloma. You may receive DARZALEX FASPRO® by itself or in combination with other multiple myeloma treatments, depending on the number of prior treatments you’ve received, or if you’re newly diagnosed and ineligible for a transplant.

DARZALEX FASPRO® was studied as a combination therapy with other medicines and as a monotherapy (by itself). You can find information about each of the studies on this site.

DARZALEX FASPRO® is given in about 3 to 5 minutes as a subcutaneous injection in the stomach area (abdomen). The dosing schedule of DARZALEX FASPRO® depends upon the treatment regimen prescribed.

You’ll be given a physical. You will also be given medicines to help reduce the risk of side effects and injection-related reactions. A healthcare professional will monitor you after your first few injections.

The most common side effects of DARZALEX FASPRO® when used alone include cold-like symptoms (upper respiratory infection).

The most common side effects of DARZALEX FASPRO® used in combination therapy include:

  • Tiredness
  • Nausea
  • Diarrhea
  • Shortness of breath
  • Trouble sleeping
  • Fever
  • Cough
  • Muscle spasms
  • Back pain
  • Vomiting
  • Cold-like symptoms (upper-respiratory infection)
  • Nerve damage causing tingling, numbness, or pain
  • Constipation
  • Lung infection (pneumonia)
  • Swollen hands, ankles, or feet

Serious allergic reactions and reactions due to release of certain substances by your body (systemic) that can lead to death, can happen with DARZALEX FASPRO®. Signs and symptoms of serious allergic reaction include:

  • Shortness of breath or trouble breathing
  • Dizziness or lightheadedness (hypotension)
  • Cough
  • Wheezing
  • Heart beating faster than usual
  • Low oxygen in the blood (hypoxia)
  • Throat tightness
  • Runny or stuffy nose
  • Headache
  • Itching
  • High blood pressure
  • Nausea
  • Vomiting
  • Chills
  • Fever
  • Chest pain

DARZALEX FASPRO® is a subcutaneous injection that takes about 3 to 5 minutes. DARZALEX® is an intravenous (IV) infusion, given through a needle placed in a vein by a healthcare professional. On average, the first infusion can take 7 hours, 4 hours for the second infusion, and 3 hours for subsequent infusions (median).

A study confirmed that DARZALEX FASPRO® gave patients results comparable to the IV formulation of DARZALEX® in treating multiple myeloma when used as monotherapy (by itself). You can see details of this study on this site.

Once you and your doctor have decided that DARZALEX FASPRO® is right for you, Janssen CarePath will help you find the resources you may need to get started and stay on track. Janssen CarePath will give you information on insurance coverage and treatment support, and identify options that may help make your treatment more affordable.

Janssen CarePath can identify cost support options that may help with managing your out-of-pocket costs – whether you have commercial or private health insurance, government coverage such as Medicare or Medicaid, or have no insurance coverage.